ADHD treatment,
without the jargon.
A clear guide to the main ADHD medicines used in the UK, how formulations differ, where non-medication treatment fits, and who can prescribe.
Medication at a glance
NICE recommends medication when ADHD symptoms continue to cause significant impairment despite appropriate environmental modifications. For adults, methylphenidate or lisdexamfetamine are first-line pharmacological options. For children aged 5 years and over and young people, methylphenidate is the first-line medicine.
Source: NICE NG87 — recommendations ↗
Methylphenidate & amphetamine-based medicines
These include methylphenidate, lisdexamfetamine and dexamfetamine. NICE notes that stimulants generally act more quickly than non-stimulants.
Atomoxetine & guanfacine
These work differently from stimulants and may be considered when stimulants are not tolerated or have not produced enough benefit. Guanfacine is principally used in children and young people.
Methylphenidate
Methylphenidate is a stimulant and a Schedule 2 controlled drug. It is available in immediate-release and modified-release forms. The NHS notes that different slow-release brands can release methylphenidate differently, which can change symptom control and how the medicine needs to be taken.
Shorter acting methylphenidate
Usually requires more than one dose across the day. It can offer flexibility, but has a higher practical burden and greater misuse/diversion concerns than long-acting formulations.
Longer-acting methylphenidate
Designed to release medicine in phases across the day. Different brands use different immediate/modified-release proportions and should not automatically be treated as interchangeable.
Common UK modified-release families
| Examples | Typical SPS profile | Practical difference |
|---|---|---|
| Concerta XL, Affenid XL, Atenza XL, Delmosart, Matoride XL, Xaggitin XL, Xenidate XL | Longer profile, around 12 hours in SPS tables | These prolonged-release tablets are grouped as bioequivalent by SPS, although brand continuity remains important in routine prescribing. |
| Equasym XL | About 8 hours; 30% immediate / 70% modified release | SPS says no other MR product is bioequivalent to Equasym XL. It is taken before breakfast. |
| Medikinet XL | About 8 hours; 50% immediate / 50% modified release | Food matters: SPS advises taking it with food. Switching requires particular care. |
| Ritalin XL, Focusim XL, Meflynate XL, Metyrol XL | About 8 hours; broadly 50/50 release profile | SPS groups these capsules as bioequivalent to one another. |
Amphetamine-based medicines
Elvanse
Lisdexamfetamine is a long-acting stimulant that is converted in the body to dexamfetamine. NICE recommends lisdexamfetamine or methylphenidate as first-line pharmacological options for adults.
Shorter-acting amphetamine
NICE says dexamfetamine can be considered when a person responds to lisdexamfetamine but cannot tolerate its longer effect profile.
Source: NICE medication choice ↗
Atomoxetine
Atomoxetine is a non-stimulant. For adults, NICE recommends it when methylphenidate and lisdexamfetamine are not tolerated or have not produced an adequate response after appropriate trials. Non-stimulants usually take longer than stimulants to show their full effect.
Guanfacine
Guanfacine is another non-stimulant option used mainly in children and young people. NICE recommends atomoxetine or guanfacine for children aged 5 years and over and young people when methylphenidate and lisdexamfetamine are not tolerated or have not worked adequately. NICE advises against offering guanfacine to adults without advice from a tertiary ADHD service.
Source: NICE NG87 ↗
How is a medicine chosen?
There is no single “best” ADHD medicine. Choice can depend on age, duration of symptom coverage needed, previous response, side effects, sleep, appetite, cardiovascular considerations, coexisting conditions, risk of misuse or diversion, formulation preferences and practical issues such as taking medication at school or work.
NICE also recommends considering modified-release once-daily stimulants for convenience, adherence, reducing stigma at school/work, and reducing storage or diversion concerns.
Who can prescribe ADHD medication?
The key distinction is between being an ADHD clinician and having legal prescribing authority. NHS SPS states that ADHD medicines should be started by an ADHD specialist — a healthcare professional with training and expertise in diagnosing and managing ADHD.
Doctors
Registered doctors can prescribe, but ADHD initiation should still sit within appropriate specialist competence and governance.
Pharmacist independent prescribers
Can prescribe medicines, including most Schedule 2–5 controlled drugs, within their clinical competence. ADHD prescribing therefore requires appropriate ADHD expertise and governance.
Nurse independent prescribers
Can prescribe medicines including most controlled drugs within competence, subject to their professional scope and local governance.
GPs under shared care
The NHS says a GP may take over ongoing ADHD prescribing when a shared-care agreement is in place between the GP and ADHD specialist.
Psychologists
Psychologist registration itself does not confer prescribing rights. A psychologist would need a separate prescribing qualification/regulated prescribing route to prescribe.
Sources: NHS SPS — ADHD medicines ↗ · NHSBSA — pharmacist prescribers ↗ · NHS — adult ADHD/shared care ↗
Titration and monitoring
Titration is the period in which medication and dose are adjusted while benefits and adverse effects are reviewed. NICE recommends recording symptoms, impairment and adverse effects at baseline and at each dose change, with regular monitoring of physical parameters such as pulse, blood pressure and weight according to age and treatment.
Non-medication treatment
Medication is not the only option. NICE recommends considering non-pharmacological treatment for adults who choose not to take medication, have difficulty adhering to it, cannot tolerate it, or find it ineffective. Structured supportive psychological interventions may include elements of cognitive behavioural therapy (CBT). Environmental modifications and practical support are relevant throughout care.
Source: NICE NG87 ↗
Primary sources used for this guide
NICE NG87
National recommendations on ADHD diagnosis, treatment choice, medication sequencing and monitoring. Read NICE ↗
NHS Specialist Pharmacy Service
Detailed professional guidance on modified-release methylphenidate products, brand equivalence and switching. Read SPS ↗
NHS
Patient-facing information on methylphenidate and adult ADHD treatment/shared care. Methylphenidate ↗ · Adult ADHD ↗